Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | AKR1B1 | P15121 | 15/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9327258 | 0.81 | MAPT (0.78) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL23914739 | 0.79 | MAPT (0.63) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL6890822 | 0.78 | MAPT (1.00) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL23966567 | 0.77 | MAPT (0.68) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL23914729 | 0.77 | RECQL (0.53) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL8957310 | 0.77 | KMT2A (0.77) | MAPTAKR1B1KMT2APTGDR2 | |
| SCHEMBL23915524 | 0.76 | MAPT (0.67) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL10007138 | 0.76 | MAPT (0.79) | MAPTAKR1B1KMT2APOLBALOX15 | |
| SCHEMBL23914958 | 0.75 | MAPT (0.61) | MAPTAKR1B1KMT2APOLB | |
| SCHEMBL8957218 | 0.75 | MAPT (0.68) | MAPTAKR1B1KMT2APOLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | MAPT 4876/4885AKR1B1 124/4885KMT2A 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.